Approval spans early and levodopa-treated disease; a 6-week titration and CYP3A interactions put pharmacists at the center of starting therapy.
|Podcasts|September 27, 2022
Pharmacy Focus: On The Shelf - All About Migraine
On this week's episode, host Joanna speaks with Charlie Conway, PhD, chief scientific officer at Biohaven Pharmaceuticals about migraine function, care, and treatment.
Advertisement
On this week's episode, host Joanna speaks with Charlie Conway, PhD, chief scientific officer at Biohaven Pharmaceuticals about migraine function, care, and treatment. Conway has 30 years of research experience, including 17 years of drug discovery and development, and specializes in neuroscience.
Advertisement
Related to this article
Novo's topline phase 3 data show 12.4% weight loss with CagriSema 1.0 mg/1.0 mg in type 2 diabetes and 21.0% in adults with overweight or obesity.
Researchers found substantial overlap in autonomic symptoms, orthostatic tachycardia, and functional impairment between long COVID and POTS.
A review of 69 studies finds influenza vaccines continue to reduce hospitalization and death, with no new safety concerns.
Isatuximab plus Iberdomide maintenance helps MRD-positive myeloma patients turn MRD-negative after transplant, with manageable safety.
Insulin efsitora alfa-gobe (Onswik; Eli Lilly and Company) is designed to deliver steady basal insulin levels over a full 7-day duration.
Vallerie McLaughlin, MD, explains why the ERS update strongly recommends sotatercept for patients with pulmonary arterial hypertension (PAH) who don't reach low-risk status on initial therapy.
Imaging data from the CONTENTed study suggest the type 2 inflammation that drives severe asthma may affect more than the airways.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Ramantamig's 93.6% ORR and Outpatient CRS Control
2
Teclistamab-Daratumumab Intensification Achieves 73% MRD-Negative CR Rate in High-Risk Multiple Myeloma
3
Nearly Two-Thirds of Patients With Long COVID Meet Diagnostic Criteria for POTS
4
Influenza Vaccines Continue to Reduce Severe Disease and Death Across High-Risk Groups, Evidence Review Finds
5